Colitis-Pipeline Review, H1 2015

Colitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6153IDB
  • |
  • Pages: 74
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Colitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Colitis-Pipeline Review, H1 2015', provides an overview of the Colitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Colitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Colitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Colitis Overview 8

Therapeutics Development 9

Pipeline Products for Colitis-Overview 9

Pipeline Products for Colitis-Comparative Analysis 10

Colitis-Therapeutics under Development by Companies 11

Colitis-Therapeutics under Investigation by Universities/Institutes 13

Colitis-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Colitis-Products under Development by Companies 16

Colitis-Products under Investigation by Universities/Institutes 17

Colitis-Companies Involved in Therapeutics Development 18

Ajinomoto Pharmaceuticals Co., Ltd. 18

Akebia Therapeutics, Inc. 19

BioLineRx, Ltd. 20

Cognosci, Inc. 21

Galapagos NV 22

GeneFrontier Corporation 23

Inovio Pharmaceuticals, Inc. 24

N30 Pharmaceuticals 25

Prokarium Ltd. 26

Protalix BioTherapeutics, Inc. 27

Synovo GmbH 28

Colitis-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

AcTMP-1-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

AKB-6899-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

APY-0201-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

BC-1215-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BL-5040-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

C-142-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

clostridium difficile vaccine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

COG-112-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

CSY-0073-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

etanercept biosimilar-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

filgotinib-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

GFC-101-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

N-6022-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

N-6547-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

NK-007-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Peptide to Inhibit NFkB for Colitis and Enteritis-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

RNAi Oligonucleotides to Inhibit TNFalpha for IBD and Colitis-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecule for Colitis-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Synthetic Peptides to Inhibit Panx1 for Colitis-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Vaccine for Colitis-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Vaccine to Target Interleukin-23 for Colitis-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

VGX-1027-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Colitis-Recent Pipeline Updates 63

Colitis-Dormant Projects 70

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

Number of Products under Development for Colitis, H1 2015 9

Number of Products under Development for Colitis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Colitis-Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2015 18

Colitis-Pipeline by Akebia Therapeutics, Inc., H1 2015 19

Colitis-Pipeline by BioLineRx, Ltd., H1 2015 20

Colitis-Pipeline by Cognosci, Inc., H1 2015 21

Colitis-Pipeline by Galapagos NV, H1 2015 22

Colitis-Pipeline by GeneFrontier Corporation, H1 2015 23

Colitis-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 24

Colitis-Pipeline by N30 Pharmaceuticals, H1 2015 25

Colitis-Pipeline by Prokarium Ltd., H1 2015 26

Colitis-Pipeline by Protalix BioTherapeutics, Inc., H1 2015 27

Colitis-Pipeline by Synovo GmbH, H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Colitis Therapeutics-Recent Pipeline Updates, H1 2015 63

Colitis-Dormant Projects, H1 2015 70

Colitis-Dormant Projects (Contd..1), H1 2015 71

Colitis-Dormant Projects (Contd..2), H1 2015 72

List of Figures

Number of Products under Development for Colitis, H1 2015 9

Number of Products under Development for Colitis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Ajinomoto Pharmaceuticals Co., Ltd.

Akebia Therapeutics, Inc.

BioLineRx, Ltd.

Cognosci, Inc.

Galapagos NV

GeneFrontier Corporation

Inovio Pharmaceuticals, Inc.

N30 Pharmaceuticals

Prokarium Ltd.

Protalix BioTherapeutics, Inc.

Synovo GmbH

Colitis Therapeutic Products under Development, Key Players in Colitis Therapeutics, Colitis Pipeline Overview, Colitis Pipeline, Colitis Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]